Structure-Based Design of a Superagonist Ligand for the Vitamin D Nuclear Receptor

Chemistry and Biology

Volumn 15, Issue 4, 2008, Pages 383-392

  Hourai, Shinji ^a   Rodrigues, Luis Cezar ^d   Antony, Pierre ^a   Reina San Martin, Bernardo ^b   Ciesielski, Fabrice ^a   Magnier, Benjamin Claude ^c   Schoonjans, Kristina ^c   Mouriño, Antonio ^d   Rochel, Natacha ^a   Moras, Dino ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

CALCITRIOL; CALCITRIOL RECEPTOR; DRUG DERIVATIVE; LIGAND; VITAMIN D;

ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; STEREOISOMERISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; CALCITRIOL; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIGANDS; MALE; MICE; RECEPTORS, CALCITRIOL; STEREOISOMERISM; TRANSCRIPTION, GENETIC; VITAMIN D;

EID: 41949120325     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.03.016     Document Type: Article

References (45)

1. Banerjee P., and Chatterjee M. Antiproliferative role of vitamin D and its analogs-a brief overview. Mol. Cell. Biochem. 253 (2003) 247-254
2. Bouillon R., Verlinden L., Eelen G., De Clercq P., Vandewalle M., Mathieu C., and Verstuyf A. Mechanisms for the selective action of vitamin D analogs. J. Steroid Biochem. Mol. Biol. 97 (2005) 21-30
3. Bouillon R., Eelen G., Verlinden L., Mathieu C., Carmeliet G., and Verstuyf A. Vitamin D and cancer. J. Steroid Biochem. Mol. Biol. 102 (2006) 156-162
4. Bourguet W., Ruff M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375 (1995) 377-382
5. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallographic & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
6. Campbell M.J., and Adorini L. The vitamin D receptor as a therapeutic target. Expert Opin. Ther. Targets 10 (2006) 735-748
7. Carlberg C., and Dunlop T.W. The impact of chromatin organization of vitamin D target genes. Anticancer Res. 26 (2006) 2637-2645
8. Champy M.F., Selloum M., Piard L., Zeitler V., Caradec C., Chambon P., and Auwerx J. Mouse functional genomics requires standardization of mouse handling and housing conditions. Mamm. Genome 15 (2004) 768-783
9. Cheskis B.J., Freedman L.P., and Nagpal S. Vitamin D receptors ligands for osteoporosis. Curr. Opin. Investig. Drugs 7 (2006) 906-911
10. Ciesielski F., Rochel N., and Moras D. Adaptability of the vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. J. Steroid Biochem. Mol. Biol. 103 (2007) 235-242
11. Ebert R., Schütze N., Adamski J., and Jakob F. Vitamin D signaling is modulated on multiple levels in health and disease. Mol. Cell. Endocrinol. 248 (2006) 149-159
12. Eelen G., Verlinden L., Rochel N., Claessens F., De Clercq P., Vandewalle M., Tocchini-Valentini G., Moras D., Bouillon R., and Verstuyf A. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 67 (2005) 1566-1573
13. El-Kabbani O., Rogniaux H., Barth P., Chung R.P.-T., Fletcher E.V., Van Dorsselear A., and Podjarny A. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site. Proteins 41 (2000) 407-414
14. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I.P., Heber D., Binderup L., Uskokovic M., and Koeffler H.P. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55 (1995) 2822-2830
15. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., Shintaku I.P., Krajewski S., Reed J.C., Binderup L., et al. Combination of a potent 20-epi-vitamin D3 analogue (KH1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 56 (1996) 3570-3576
16. Fernández B., Martínez-Perez J.A., Granja J.R., Castedo L., and Mouriño A. Synthesis of hydrindan derivatives related to vitamin D. J. Org. Chem. 57 (1992) 3173-3178
17. Holick M.F. Vitamin D: a millenium perspective. J. Cell. Biochem. 88 (2003) 296-307
18. Hourai S., Fujishima T., Kittaka A., Suhara Y., Takayama H., Rochel N., and Moras D. Probing a water channel near the A-ring of receptor-bound 1α,25-dihydroxyvitamin D3 with selected 2α-substituted analogues. J. Med. Chem. 49 (2006) 5199-5205
19. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
20. Kabat M.M., and Radinov R. The practical synthesis of vitamin D analogs: a challenge for process research. Curr. Opin. Drug Discov. Devel. 4 (2001) 808-833
21. Laudet V., and Gronemeyer H. The Nuclear Receptor Facts Book (2002), Academic Press, London
22. Lonard D.M., and O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125 (2006) 411-414
23. Lythgoe B. Synthetic approaches to vitamin D and its relatives. Chem. Soc. Rev. 9 (1980) 449-475
24. McCarthy D.M., San Miguel J.F., Freake H.C., Green P.M., Zola H., Catovsky D., and Goldman J.M. 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk. Res. 7 (1983) 51-55
25. 3 and analogues. Application to the synthesis of Lythgoe-Roche phosphine oxide. Tetrahedron Lett. 38 (1997) 4713-4716
26. Nagpal S., Na S., and Rathnachalam R. Noncalcemic actions of vitamin D receptors ligands. Endocr. Rev. 26 (2005) 662-687
27. Norman A.W., Mizwicki M.T., and Norman D.P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 3 (2004) 27-41
28. Onate S.A., Tsai S.Y., Tsai M.J., and O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 (1995) 1354-1357
29. Otwinowski Z., and Minor W. Processing of X-ray data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
30. Pakkala S., de Vos S., Elstner E., Rude R.K., Uskokovic M., Binderup L., and Koeffler H.P. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk. Res. 19 (1995) 65-72
31. Peleg S., Sastry M., Collins E.D., Bishop J.E., and Norman A.W. Distinct conformational changes induced by 20-epi analogues of 1α,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 270 (1995) 10551-10558
32. Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M., Näär A.M., Erdjument-Bromage H., Tempst P., and Freedman L.P. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398 (1999) 824-828
33. Reddy G.S., Robinson M., Wang G., Palmore G.T., Gennaro L., Vouros P., De Clercq P., Vandewalle M., Young W., Ling S., et al. Removal of C-ring from the CD-ring skeleton of 1α,25-dihydroxyvitamin D3 does not alter its target tissue metabolism significantly. Arch. Biochem. Biophys. 460 (2007) 254-261
34. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378 (1995) 681-689
35. Rochel N., and Moras D. Ligand binding domain of vitamin D receptors. Curr. Top. Med. Chem. 6 (2006) 1229-1241
36. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., and Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 5 (2000) 173-179
37. Rochel N., Tocchini-Valentini G., Egea P.F., Juntunen K., Garnier J.M., Vihko P., and Moras D. Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur. J. Biochem. 268 (2001) 971-979
38. Rogniaux H., Van Dorsselaer A., Barth P., Biellmann J.F., Barbanton J., van Zandt M., Chevrier B., Howard E., Mitschler A., Potier N., et al. Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies. J. Am. Soc. Mass Spectrom. 10 (1999) 635-647
39. Tocchini-Valentini G., Rochel N., Wurtz J.M., Mitschler A., and Moras D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. USA 98 (2001) 5491-5496
40. Tocchini-Valentini G., Rochel N., Wurtz J.M., and Moras D. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J. Med. Chem. 47 (2004) 1956-1961
41. Vagin A., and Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56 (2000) 1622-1624
42. Vanhooke J.L., Benning M.M., Bauer C.B., Pike J.W., and DeLuca H.F. Molecular strucutre of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 43 (2004) 4101-4110
43. Verlinden L., Verstuyf A., Van Camp M., Marcelis S., Sabbe K., Zhao X.Y., De Clercq P., Vandewalle M., and Bouillon R. The novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 2673-2679
44. White S.L., Belov L., Barber N., Hodgkin P.D., and Christopherson R.I. Immunophenotypic changes induced on human HL60 leukaemia cells by 1α,25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk. Res. 29 (2005) 1141-1151
45. Yamada S., Shimizu M., and Yamamoto K. Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med. Res. Rev. 23 (2003) 89-115